Previous 10 | Next 10 |
home / stock / ophlf / ophlf news
2023-08-31 06:45:33 ET More on Twist Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand Twist Bioscience: Evaluating Its Conglomerate Of Innovation, Growth, And Vulnerabilities Twist Bioscience Corporation ( TWST ) Q3 2023 Earnings Call Trans...
2023-08-16 09:05:49 ET Summary Fate Therapeutics is a cell therapy company focused on CAR-T and NK cells for autoimmune diseases and cancer. Their product candidates are still in early clinical trials or preclinical stages, making their path forward uncertain. The company has ...
2023-05-11 10:29:16 ET Ono Pharmaceutical press release ( OTCPK:OPHLF ): FY GAAP EPS of ¥230.79. Revenue of ¥447.18B (+23.7% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥230.79, revenue of ¥447.18B
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Ono Pharmaceutical press release ( OTCPK:OPHLF ): Q2 GAAP EPS of ¥127.66. Revenue of ¥216.7B (+24.5% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥127.66, revenue of ¥216.7B
Ono Pharmaceutical press release ( OTCPK:OPHLF ): Q1 GAAP EPS of ¥60.36. Revenue of ¥106.72B (+22.2% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥60.36, revenue of ¥106.72B
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
eFFECTOR Therapeutics is a biopharmaceutical company focused on development of selective translation regulation inhibitors (STRIs) for treating cancer. CEO Dr. Steve Worland discusses its 2 drugs in clinical trials and collaboration with Pfizer. Going public in Q3 2021 through SPA...
The following slide deck was published by Ono Pharmaceutical Co., Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Ono Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation
Ono Pharmaceutical (OTC:OPHLF): Q1 GAAP EPS of ¥48.22. Revenue of ¥87.36B (+16.6% Y/Y). Press Release For further details see: Ono Pharmaceutical reports Q1 results
News, Short Squeeze, Breakout and More Instantly...
Ono Pharmaceutical Co Ltd Company Name:
OPHLF Stock Symbol:
OTCMKTS Market:
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Ebix Inc. (EBIXQ) is expected to report for Q1 2024 Amesite Inc. (AMST) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.68 for Q1 2025 Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A) (WDH) is expected to repo...
TDCX Inc. American Depositary Shares each representing one Class A (TDCX) is expected to report for Q1 2024 nCino Inc. (NCNO) is expected to report $0 for Q1 2025 SK Telecom Co. Ltd. (SKM) is expected to report for Q1 2024 Redeia Corporacion S.A. ADR (RDEIY) is expected to report for ...